Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.560 -0.160 (-4.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Why Shares of Editas Medicine Jumped This Week
It's been a seesaw month for the clinical-stage gene-editing biotech. 
Via The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
 
Via Benzinga
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
Analyst Expectations for Editas Medicine's Future
 
Via Benzinga
Why Editas Medicine Stock Is Sliding Today
The gene-editing pioneer announced a big shake-up with its research and development programs. 
Via The Motley Fool
Analyst Ratings for Editas Medicine
 
Via Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
The biotech's shares plummeted after it paused a key clinical trial. 
Via The Motley Fool
Why Editas Medicine's Shares Are Falling Thursday
The company shelved a clinical trial for one of its lead therapies. 
Via The Motley Fool
Editas Medicine: Q3 Earnings Insights
Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
These biotechs could skyrocket in 2023, but only if they can execute their plans. 
Via The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
 
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
The company could continue lagging the market for a while. 
Via The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
Via Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on... 
Via Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
  Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday. 
Via Benzinga
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. 
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Editas Medicine
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades 
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.